George Kolios

George Kolios is Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece. He obtained his first degree in Medicine in 1980. In 1992, he obtained his PhD degree in Gastroenterology from the School of Medicine at the University of Athens, Greece and in 1998, his PhD degree in Pharmacology from the Department of Pharmacology at the University of Bath, United Kingdom. In 1990, he finished his Specialization in Gastroenterology and he first worked as Registrar in Gastroenterology at the Royal United Hospital, Bath, United Kingdom and then as Senior Registrar in the Gastroenterology Department at the Hippokration General Hospital, Athens, Greece. From 1998 till 2001, he worked as Consultant Gastroenterologist at the Royal United Hospital, Bath, and Senior Research Fellow in the Department of Pharmacology at the University of Bath, United Kingdom. In 2001, he was appointed Assistant Professor of Gastroenterology in the School of Medicine at the University of Crete and Visiting Professor in Pharmacology at the University of Bath, United Kingdom. From 2008 till today, he is a Professor of Pharmacology in the School of Medicine at the Democritus University of Thrace, Alexandroupolis, Greece and Director of the Master’s Degree Program “Clinical Pharmacology and Therapeutics” that is organized by the School of Medicine of Democritus University of Thrace. From 2008 till 2013, he was Member of the Scientific Board of Approvals of the Greek National Organization for Medicines. From 2013 till today, Professor Kolios is Vise-President of the School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Professor George Kolios is an experienced Clinical Gastroenterologist, and a very productive research scientist, with an extensive work in the area of immunopharmacology, mucosal immunology and fibrosis, mainly focused on the intestinal inflammation and Inflammatory Bowel Diseases. His work has demonstrated that the mucosal epithelium could be a rich source of various inflammatory mediators, including cytokines, chemokines and nitric oxide, which are involved in inflammation and fibrosis, and that these pro-inflammatory systems can be modified by cytokines derived by T-cell population. In addition, his work has been focused on the biology and the role of gut subepithelial myofibroblasts in fibrosis and on the interplay between gut mucosal immunity and microbiota. He has more than 80 papers in peer reviewed journals, which have been cited more than 3100 times with an h-index: 31.